Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., Fed. Cir., Nos. 16-1284, 7/14/2017
All documents are in PDF format.
A Federal Circuit panel misconstrued the statutory language and legislative history of 35 U.S.C. 102(a)(1), as amended by the America Invents Act (AIA), when it invalidated a patent based on a press release and SEC filing about a sales agreement by the patent owner, according to an AIPLA amicus brief urging en banc review of the case.
The brief explains that the panel failed to recognize that the AIA abandoned the so called "on-sale bar" for sales more than a year before the filing date, instead establishing the prior art effect for sales available to the public before the application's "effective filing date," defined in 35 U.S.C. 100(i). The panel opinion conflicts with the premises of transparency and predictability that underlie the changes enacted by the AIA, according to the brief.
AIPLA 2020 Trade Secret Law Summit - Weekly Webinar Series
August 12 to September 2, 2020 | Each Session is eligible for 90 minutes of CLE where applicableFor the first time in this event's history, we are switching to an immersive virtual experience. The 2020 Trade Secret Law Summit will be presented in four easy-to-schedule-around sessions that you can join from your computer or mobile device.
2020 VIRTUAL PTAB Bench + Bar
August 20, 2020 3:00 PM to 6:00 PM (Eastern Daylight Time)Engage Directly with PTAB Leaders and Judges. Gain an edge by learning about the latest at the PTAB. Register today!
AIPLA 2020 Virtual Annual Meeting
October 22 to 30, 2020The AIPLA 2020 Virtual Annual Meeting is your platform to learn, network, and plot the next steps in your career as you find ways to unlock your potential.